Memphasys Ltd (AU:MEM) has released an update.
Don't Miss our Black Friday Offers:
- Unlock your investing potential with TipRanks Premium - Now At 40% OFF!
- Make smarter investments with weekly expert stock picks from the Smart Investor Newsletter
Memphasys Ltd, a pioneering Australian biotechnology firm, is inviting shareholders to a webinar to share updates on its Felix System clinical trials, which are nearing completion. The company is eyeing a quicker entry into the European market with a fast-tracked regulatory strategy. Additionally, Memphasys has embarked on a 3-year equine study expected to yield commercial results within a year.
For further insights into AU:MEM stock, check out TipRanks’ Stock Analysis page.
